Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies

Leukemia & Lymphoma
Barry HockJ L McKenzie

Abstract

The release of soluble forms of CD80 provides a potentially powerful mechanism for the modulation of anti-tumor responses. In this report we investigated whether a soluble form of CD80 (sCD80) circulates in vivo and whether levels are altered in patients with hematological malignancies. Circulating sCD80 was detected by ELISA in all normal donor (0.024-0.318 ng/ml) and patient (0.02-3.75 ng/ml) blood analyzed. The majority of acute myeloid leukemia (13/17) and multiple myeloma (11/12) patients had normal sCD80 levels. Significantly elevated levels were detected in chronic lymphocytic leukemia (CLL, P = 0.0001) and mantle cell lymphoma (MCL, P = 0.0002) patients. MCL patients had the highest levels with 8/9 having levels > 0.318 ng/ml. Increased sCD80 levels in CLL were significantly associated with poor prognosis markers such as low platelet (P = 0.01) and hemoglobin (P = 0.002) levels, elevated WBC counts (P = 0.03) and expression of CD38 (P = 0.048). The immunoreactivity of the sCD80 in both normal and patient plasma was inhibited by the presence of CTLA-4-Ig, suggesting sCD80 is functional. Comparison of sCD80 and soluble CD86 levels demonstrated that these molecules were independently elevated in 39% of patients. The findin...Continue Reading

References

Nov 1, 1995·The Journal of Experimental Medicine·T C WuD M Pardoll
Nov 4, 1993·Nature·M AzumaC Somoza
Nov 18, 1998·Current Opinion in Oncology·D N LiebowitzC H June
Dec 29, 1998·Science·Z Werb, Y Yan
Dec 30, 1998·Leukemia & Lymphoma·R D BrownD E Joshua
May 21, 1999·Biochemical and Biophysical Research Communications·G MagistrelliY Delneste
Jun 8, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·S J FaasR P Rother
Aug 11, 2001·Veterinary Immunology and Immunopathology·S YangG K Sim
Dec 1, 2001·The Journal of Biological Chemistry·Susmit SuvasJaved N Agrewala
Mar 26, 2002·Nature Reviews. Immunology·Arlene H Sharpe, Gordon J Freeman
Jul 10, 2002·Trends in Immunology·Hinrich AbkenBarbara Seliger
Aug 28, 2002·Immunity·Alison V CollinsSimon J Davis

❮ Previous
Next ❯

Citations

Jul 4, 2008·Blood·Kakushi MatsushitaRobert J Kreitman
Mar 1, 2006·Expert Opinion on Emerging Drugs·Karen W L Yee, Susan M O'Brien
Mar 25, 2010·Scandinavian Journal of Clinical and Laboratory Investigation·Priya SakthivelLars Lind
Mar 11, 2008·Trends in Immunology·Minka Breloer, Bernhard Fleischer
Feb 25, 2009·International Journal of Cancer. Journal International Du Cancer·Robert J BiggarMads Melbye
Feb 24, 2018·Cell Research·Xuexiang DuYang Liu
Nov 25, 2018·Scientific Reports·Shogo MinamikawaKazumoto Iijima
Jul 29, 2020·Cancer Reports·Rituparna ChakrabartiGayatri Mukherjee
Nov 30, 2018·Journal for Immunotherapy of Cancer·Daqian GuXiang Xu
May 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jean-Charles SoriaScott Gettinger
Apr 1, 2021·Medical Oncology·Tatiana Cunha PereiraGabriela Sousa

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.